$IMUX
Immunic Inc

2015 Q2 Form 10-Q Financial Statement

#000119312515183945 Filed on May 12, 2015

View on sec.gov

Income Statement

Concept 2015 Q2 2015 Q1 2014 Q1
Revenue $0.00 $0.00 $0.00
YoY Change
Cost Of Revenue $0.00
YoY Change
Gross Profit $0.00
YoY Change
Gross Profit Margin
Selling, General & Admin $3.530M $3.060M $2.660M
YoY Change 40.64% 15.04% 78.52%
% of Gross Profit
Research & Development $11.55M $11.75M $9.219M
YoY Change 26.52% 27.49% 168.62%
% of Gross Profit
Depreciation & Amortization $328.0K $294.0K $297.0K
YoY Change 33.33% -1.01% 82.21%
% of Gross Profit
Operating Expenses $15.08M $14.82M $11.88M
YoY Change 29.56% 24.76% 141.09%
Operating Profit -$15.08M -$14.82M -$11.88M
YoY Change 29.56% 24.76% 141.09%
Interest Expense $10.00K $10.00K $0.00
YoY Change 0.0%
% of Operating Profit
Other Income/Expense, Net -$28.00K $59.00K $1.128M
YoY Change -101.9% -94.77% -125.45%
Pretax Income -$15.11M -$14.76M -$10.75M
YoY Change 48.57% 37.3% 14.85%
Income Tax $0.00
% Of Pretax Income
Net Earnings -$15.11M -$14.76M -$10.75M
YoY Change 48.58% 37.31% 14.85%
Net Earnings / Revenue
Basic Earnings Per Share
Diluted Earnings Per Share -$25.18M -$24.60M -$20.28M
COMMON SHARES
Basic Shares Outstanding 24.01M shares 23.99M shares
Diluted Shares Outstanding

Balance Sheet

Concept 2015 Q2 2015 Q1 2014 Q1
SHORT-TERM ASSETS
Cash & Short-Term Investments $71.90M $88.30M $46.00M
YoY Change -20.81% 91.96% 183.95%
Cash & Equivalents $71.95M $88.26M $46.04M
Short-Term Investments
Other Short-Term Assets $3.500M $2.300M $6.200M
YoY Change 34.62% -62.9% 675.0%
Inventory
Prepaid Expenses
Receivables
Other Receivables
Total Short-Term Assets $75.45M $90.62M $52.26M
YoY Change -19.3% 73.39% 207.44%
LONG-TERM ASSETS
Property, Plant & Equipment $4.212M $4.108M $3.081M
YoY Change 29.04% 33.33% 156.75%
Goodwill
YoY Change
Intangibles
YoY Change
Long-Term Investments
YoY Change
Other Assets $214.0K $198.0K $263.0K
YoY Change -18.63% -24.71%
Total Long-Term Assets $4.426M $4.306M $3.344M
YoY Change 25.49% 28.77% 178.67%
TOTAL ASSETS
Total Short-Term Assets $75.45M $90.62M $52.26M
Total Long-Term Assets $4.426M $4.306M $3.344M
Total Assets $79.87M $94.92M $55.61M
YoY Change -17.67% 70.7% 205.54%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable $920.0K $1.128M $1.325M
YoY Change -37.03% -14.87% 10.42%
Accrued Expenses $8.852M $9.591M $5.496M
YoY Change 52.46% 74.51% 587.0%
Deferred Revenue
YoY Change
Short-Term Debt $0.00 $0.00 $0.00
YoY Change
Long-Term Debt Due
YoY Change
Total Short-Term Liabilities $9.977M $10.95M $8.633M
YoY Change 31.95% 26.79% 19.9%
LONG-TERM LIABILITIES
Long-Term Debt $0.00 $0.00 $0.00
YoY Change
Other Long-Term Liabilities $159.0K $200.0K $279.0K
YoY Change -45.55% -28.32%
Total Long-Term Liabilities $159.0K $200.0K $279.0K
YoY Change -45.55% -28.32%
TOTAL LIABILITIES
Total Short-Term Liabilities $9.977M $10.95M $8.633M
Total Long-Term Liabilities $159.0K $200.0K $279.0K
Total Liabilities $10.14M $11.15M $8.912M
YoY Change 29.07% 25.07% 23.78%
SHAREHOLDERS EQUITY
Retained Earnings -$180.7M -$165.6M
YoY Change 45.63%
Common Stock $2.000K $2.000K $0.00
YoY Change 0.0%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity $69.74M $83.78M -$58.02M
YoY Change
Total Liabilities & Shareholders Equity $79.87M $94.92M $55.61M
YoY Change -17.67% 70.7% 205.54%

Cashflow Statement

Concept 2015 Q2 2015 Q1 2014 Q1
OPERATING ACTIVITIES
Net Income -$15.11M -$14.76M -$10.75M
YoY Change 48.58% 37.31% 14.85%
Depreciation, Depletion And Amortization $328.0K $294.0K $297.0K
YoY Change 33.33% -1.01% 82.21%
Cash From Operating Activities -$15.11M -$13.51M -$9.360M
YoY Change 52.94% 44.34% 105.26%
INVESTING ACTIVITIES
Capital Expenditures -$1.310M $674.0K $809.0K
YoY Change 445.83% -16.69% 574.17%
Acquisitions
YoY Change
Other Investing Activities $120.0K $60.00K -$40.00K
YoY Change -152.17% -250.0% -100.99%
Cash From Investing Activities -$1.190M -$620.0K -$850.0K
YoY Change 153.19% -27.06% -121.68%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net $0.00 $0.00
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities 0.000 140.0K 18.07M
YoY Change -100.0% -99.23% 682.25%
NET CHANGE
Cash From Operating Activities -15.11M -13.51M -9.360M
Cash From Investing Activities -1.190M -620.0K -850.0K
Cash From Financing Activities 0.000 140.0K 18.07M
Net Change In Cash -16.30M -13.99M 7.860M
YoY Change -136.39% -277.99% 370.66%
FREE CASH FLOW
Cash From Operating Activities -$15.11M -$13.51M -$9.360M
Capital Expenditures -$1.310M $674.0K $809.0K
Free Cash Flow -$13.80M -$14.18M -$10.17M
YoY Change 43.15% 39.48% 117.29%

Facts In Submission

Frame Concept Type Concept / XBRL Key Value Unit
CY2014Q1 us-gaap Share Price
SharePrice
7.55
CY2015Q2 dei Entity Common Stock Shares Outstanding
EntityCommonStockSharesOutstanding
24012313 shares
CY2014Q1 us-gaap Share Price
SharePrice
11.30
CY2014Q1 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
46041000
CY2015Q1 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
24010351 shares
CY2015Q1 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
23982786 shares
CY2015Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber
3164500 shares
CY2015Q1 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
130000000 shares
CY2015Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
7.87
CY2015Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber
2958072 shares
CY2015Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice
6.72
CY2015Q1 us-gaap Class Of Warrant Or Right Exercise Price Of Warrants Or Rights1
ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
95.21
CY2013Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
38186000
CY2014Q4 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
24010351 shares
CY2014Q4 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
23982786 shares
CY2015Q1 us-gaap Preferred Stock Shares Outstanding
PreferredStockSharesOutstanding
0 shares
CY2015Q1 us-gaap Class Of Warrant Or Right Outstanding
ClassOfWarrantOrRightOutstanding
250646 shares
CY2015Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Outstanding Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice
7.78
CY2015Q1 us-gaap Common Stock Capital Shares Reserved For Future Issuance
CommonStockCapitalSharesReservedForFutureIssuance
3807578 shares
CY2015Q1 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.0001
CY2015Q1 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
20000000 shares
CY2015Q1 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.0001
CY2015Q1 us-gaap Preferred Stock Shares Issued
PreferredStockSharesIssued
0 shares
CY2015Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Number Of Shares Available For Grant
ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant
323919 shares
CY2015Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
3233013 shares
CY2015Q1 us-gaap Other Liabilities Current
OtherLiabilitiesCurrent
227000
CY2015Q1 us-gaap Deferred Rent Credit Current
DeferredRentCreditCurrent
130000
CY2015Q1 us-gaap Accumulated Depreciation Depletion And Amortization Property Plant And Equipment
AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
7072000
CY2015Q1 us-gaap Preferred Stock Value
PreferredStockValue
CY2015Q1 us-gaap Liabilities Current
LiabilitiesCurrent
10946000
CY2015Q1 us-gaap Common Stock Value
CommonStockValue
2000
CY2015Q1 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
CY2015Q1 us-gaap Accumulated Other Comprehensive Income Loss Net Of Tax
AccumulatedOtherComprehensiveIncomeLossNetOfTax
90000
CY2015Q1 us-gaap Accounts Payable Current
AccountsPayableCurrent
1128000
CY2015Q1 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-165590000
CY2015Q1 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
9591000
CY2015Q1 us-gaap Stockholders Equity
StockholdersEquity
83778000
CY2015Q1 us-gaap Other Liabilities Noncurrent
OtherLiabilitiesNoncurrent
200000
CY2015Q1 us-gaap Other Accrued Liabilities Current
OtherAccruedLiabilitiesCurrent
540000
CY2015Q1 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
94924000
CY2015Q1 us-gaap Additional Paid In Capital
AdditionalPaidInCapital
249276000
CY2015Q1 us-gaap Employee Related Liabilities Current
EmployeeRelatedLiabilitiesCurrent
1551000
CY2015Q1 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
88257000
CY2015Q1 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
4108000
CY2015Q1 us-gaap Restricted Cash And Cash Equivalents At Carrying Value
RestrictedCashAndCashEquivalentsAtCarryingValue
1533000
CY2015Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Intrinsic Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue
55448771
CY2015Q1 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
828000
CY2015Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Outstanding Aggregate Intrinsic Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue
54555223
CY2015Q1 us-gaap Property Plant And Equipment Gross
PropertyPlantAndEquipmentGross
11180000
CY2015Q1 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Exercisable Intrinsic Value1
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1
54091498
CY2015Q1 us-gaap Assets
Assets
94924000
CY2015Q1 us-gaap Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized
EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized
6300000
CY2015Q1 us-gaap Other Assets Noncurrent
OtherAssetsNoncurrent
198000
CY2015Q1 us-gaap Assets Current
AssetsCurrent
90618000
CY2015Q1 vtl Accrued Capital Costs
AccruedCapitalCosts
845000
CY2015Q1 vtl Accrued Clinical Costs
AccruedClinicalCosts
6655000
CY2013Q4 us-gaap Share Price
SharePrice
5.93
CY2014Q4 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
130000000 shares
CY2014Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
7.54
CY2014Q4 us-gaap Preferred Stock Shares Outstanding
PreferredStockSharesOutstanding
0 shares
CY2014Q4 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.0001
CY2014Q4 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
20000000 shares
CY2014Q4 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-150833000
CY2014Q4 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.0001
CY2014Q4 us-gaap Preferred Stock Shares Issued
PreferredStockSharesIssued
0 shares
CY2014Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
3210693 shares
CY2014Q4 us-gaap Other Liabilities Current
OtherLiabilitiesCurrent
250000
CY2014Q4 us-gaap Deferred Rent Credit Current
DeferredRentCreditCurrent
126000
CY2014Q4 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
8875000
CY2014Q1 us-gaap Operating Income Loss
OperatingIncomeLoss
-11876000
CY2014Q4 us-gaap Accumulated Depreciation Depletion And Amortization Property Plant And Equipment
AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
6778000
CY2014Q4 us-gaap Preferred Stock Value
PreferredStockValue
CY2014Q4 us-gaap Liabilities Current
LiabilitiesCurrent
10278000
CY2014Q4 us-gaap Common Stock Value
CommonStockValue
2000
CY2014Q4 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
CY2014Q4 us-gaap Accumulated Other Comprehensive Income Loss Net Of Tax
AccumulatedOtherComprehensiveIncomeLossNetOfTax
89000
CY2014Q4 us-gaap Accounts Payable Current
AccountsPayableCurrent
1153000
CY2014Q4 us-gaap Stockholders Equity
StockholdersEquity
97563000
CY2014Q4 us-gaap Other Liabilities Noncurrent
OtherLiabilitiesNoncurrent
241000
CY2014Q4 us-gaap Other Accrued Liabilities Current
OtherAccruedLiabilitiesCurrent
197000
CY2014Q4 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
108082000
CY2014Q4 us-gaap Additional Paid In Capital
AdditionalPaidInCapital
248305000
CY2014Q4 us-gaap Employee Related Liabilities Current
EmployeeRelatedLiabilitiesCurrent
2554000
CY2014Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
102238000
CY2014Q4 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
3068000
CY2014Q4 us-gaap Restricted Cash And Cash Equivalents At Carrying Value
RestrictedCashAndCashEquivalentsAtCarryingValue
1592000
CY2014Q4 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
986000
CY2014Q4 us-gaap Property Plant And Equipment Gross
PropertyPlantAndEquipmentGross
9846000
CY2014Q4 us-gaap Assets
Assets
108082000
CY2014Q4 us-gaap Other Assets Noncurrent
OtherAssetsNoncurrent
198000
CY2014Q4 us-gaap Assets Current
AssetsCurrent
104816000
CY2014Q4 vtl Accrued Capital Costs
AccruedCapitalCosts
52000
CY2014Q4 vtl Accrued Clinical Costs
AccruedClinicalCosts
6072000
CY2014Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Weighted Average Grant Date Fair Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
5.17
CY2014Q1 us-gaap Net Cash Provided By Used In Operating Activities Continuing Operations
NetCashProvidedByUsedInOperatingActivitiesContinuingOperations
-9364000
CY2014Q1 us-gaap Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
564186 shares
CY2014Q1 us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-24.49
CY2014Q1 us-gaap Payments Of Stock Issuance Costs
PaymentsOfStockIssuanceCosts
94000
CY2014Q1 us-gaap Increase Decrease In Restricted Cash
IncreaseDecreaseInRestrictedCash
44000
CY2014Q1 us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
81000
CY2014Q1 us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
809000
CY2014Q1 us-gaap Other Noncash Income Expense
OtherNoncashIncomeExpense
45000
CY2014Q1 us-gaap Net Income Loss Available To Common Stockholders Basic
NetIncomeLossAvailableToCommonStockholdersBasic
-13818000
CY2014Q1 us-gaap Net Income Loss
NetIncomeLoss
-10748000
CY2014Q1 us-gaap Investment Income Interest
InvestmentIncomeInterest
2000
CY2014Q1 us-gaap Capital Expenditures Incurred But Not Yet Paid
CapitalExpendituresIncurredButNotYetPaid
102000
CY2014Q1 us-gaap Depreciation Depletion And Amortization
DepreciationDepletionAndAmortization
297000
CY2014Q1 us-gaap Net Cash Provided By Used In Investing Activities Continuing Operations
NetCashProvidedByUsedInInvestingActivitiesContinuingOperations
-853000
CY2014Q1 us-gaap Effect Of Exchange Rate On Cash And Cash Equivalents Continuing Operations
EffectOfExchangeRateOnCashAndCashEquivalentsContinuingOperations
-1000
CY2014Q1 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
2657000
CY2014Q1 us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-10749000
CY2014Q1 us-gaap Other Comprehensive Income Foreign Currency Transaction And Translation Adjustment Net Of Tax Portion Attributable To Parent
OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent
-1000
CY2014Q1 us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
1128000
CY2014Q1 us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
-2000
CY2014Q1 us-gaap Operating Expenses
OperatingExpenses
11876000
CY2014Q1 us-gaap Proceeds From Issuance Of Preferred Stock And Preference Stock
ProceedsFromIssuanceOfPreferredStockAndPreferenceStock
18167000
CY2014Q1 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
9219000
CY2014Q1 us-gaap Cash And Cash Equivalents Period Increase Decrease
CashAndCashEquivalentsPeriodIncreaseDecrease
7855000
CY2014Q1 us-gaap Operating Leases Rent Expense Net
OperatingLeasesRentExpenseNet
183000
CY2014Q1 us-gaap Temporary Equity Accretion To Redemption Value Adjustment
TemporaryEquityAccretionToRedemptionValueAdjustment
3048000
CY2014Q1 us-gaap Net Cash Provided By Used In Financing Activities Continuing Operations
NetCashProvidedByUsedInFinancingActivitiesContinuingOperations
18073000
CY2014Q1 us-gaap Temporary Equity Dividends Adjustment
TemporaryEquityDividendsAdjustment
22000
CY2014Q1 us-gaap Increase Decrease In Accrued Liabilities
IncreaseDecreaseInAccruedLiabilities
1964000
CY2014Q1 us-gaap Increase Decrease In Accounts Payable
IncreaseDecreaseInAccountsPayable
-58000
CY2014Q1 us-gaap Share Based Compensation
ShareBasedCompensation
435000
CY2014Q1 vtl Release Of Repurchase Liability For Stock Options Shares Vested During Period
ReleaseOfRepurchaseLiabilityForStockOptionsSharesVestedDuringPeriod
26000
CY2014Q1 vtl Gain Loss On Revaluation Of Future Purchase Rights Liabilities
GainLossOnRevaluationOfFuturePurchaseRightsLiabilities
1128000
CY2014Q1 vtl Deferred Financing Costs Included In Liabilities
DeferredFinancingCostsIncludedInLiabilities
336000
CY2015Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod
63683 shares
CY2015Q1 us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Exercises In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice
5.16
CY2015Q1 dei Document Type
DocumentType
10-Q
CY2015Q1 dei Entity Registrant Name
EntityRegistrantName
VITAL THERAPIES INC
CY2015Q1 dei Trading Symbol
TradingSymbol
VTL
CY2015Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Weighted Average Grant Date Fair Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
17.87
CY2015Q1 dei Entity Filer Category
EntityFilerCategory
Non-accelerated Filer
CY2015Q1 us-gaap Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized Period For Recognition1
EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1
P2Y
CY2015Q1 us-gaap Net Cash Provided By Used In Operating Activities Continuing Operations
NetCashProvidedByUsedInOperatingActivitiesContinuingOperations
-13506000
CY2015Q1 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Vested And Expected To Vest Exercisable Weighted Average Remaining Contractual Term1
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1
P7Y9M18D
CY2015Q1 us-gaap Use Of Estimates
UseOfEstimates
<div> <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 4%; MARGIN-TOP: 6pt"> <b><i>Use of Estimates</i></b></p> <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 6pt; TEXT-INDENT: 4%"> The preparation of financial statements in conformity with GAAP requires us to make certain estimates and assumptions that affect the amounts reported in the consolidated financial statements and accompanying notes. Actual results could differ materially from those estimates and assumptions.</p> </div>
CY2015Q1 us-gaap Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
23972599 shares
CY2015Q1 dei Document Period End Date
DocumentPeriodEndDate
2015-03-31
CY2015Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures And Expirations In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice
8.00
CY2015Q1 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Outstanding Weighted Average Remaining Contractual Term2
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2
P7Y9M18D
CY2015Q1 dei Amendment Flag
AmendmentFlag
false
CY2015Q1 dei Current Fiscal Year End Date
CurrentFiscalYearEndDate
--12-31
CY2015Q1 dei Document Fiscal Year Focus
DocumentFiscalYearFocus
2015
CY2015Q1 us-gaap Fair Value Assumptions Expected Dividend Rate
FairValueAssumptionsExpectedDividendRate
0.000 pure
CY2015Q1 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Exercisable Weighted Average Remaining Contractual Term1
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1
P7Y8M12D
CY2015Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures And Expirations In Period
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod
13799 shares
CY2015Q1 us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Grants In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice
23.68
CY2015Q1 dei Entity Central Index Key
EntityCentralIndexKey
0001280776
CY2015Q1 us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-0.62
CY2015Q1 dei Document Fiscal Period Focus
DocumentFiscalPeriodFocus
Q1
CY2015Q1 us-gaap Stock Issued During Period Shares Stock Options Exercised
StockIssuedDuringPeriodSharesStockOptionsExercised
27564 shares
CY2015Q1 us-gaap Increase Decrease In Restricted Cash
IncreaseDecreaseInRestrictedCash
-59000
CY2015Q1 us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
-162000
CY2015Q1 us-gaap Operating Income Loss
OperatingIncomeLoss
-14817000
CY2015Q1 us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-14757000
CY2015Q1 us-gaap Other Comprehensive Income Foreign Currency Transaction And Translation Adjustment Net Of Tax Portion Attributable To Parent
OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent
1000
CY2015Q1 us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
59000
CY2015Q1 us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
49000
CY2015Q1 us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
674000
CY2015Q1 us-gaap Net Income Loss Available To Common Stockholders Basic
NetIncomeLossAvailableToCommonStockholdersBasic
-14758000
CY2015Q1 us-gaap Net Income Loss
NetIncomeLoss
-14758000
CY2015Q1 us-gaap Investment Income Interest
InvestmentIncomeInterest
10000
CY2015Q1 us-gaap Capital Expenditures Incurred But Not Yet Paid
CapitalExpendituresIncurredButNotYetPaid
934000
CY2015Q1 us-gaap Depreciation Depletion And Amortization
DepreciationDepletionAndAmortization
294000
CY2015Q1 us-gaap Operating Expenses
OperatingExpenses
14817000
CY2015Q1 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
11753000
CY2015Q1 us-gaap Cash And Cash Equivalents Period Increase Decrease
CashAndCashEquivalentsPeriodIncreaseDecrease
-13981000
CY2015Q1 us-gaap Operating Leases Rent Expense Net
OperatingLeasesRentExpenseNet
225000
CY2015Q1 us-gaap Net Cash Provided By Used In Financing Activities Continuing Operations
NetCashProvidedByUsedInFinancingActivitiesContinuingOperations
139000
CY2015Q1 us-gaap Increase Decrease In Accrued Liabilities
IncreaseDecreaseInAccruedLiabilities
-80000
CY2015Q1 us-gaap Net Cash Provided By Used In Investing Activities Continuing Operations
NetCashProvidedByUsedInInvestingActivitiesContinuingOperations
-615000
CY2015Q1 us-gaap Proceeds From Stock Options Exercised
ProceedsFromStockOptionsExercised
139000
CY2015Q1 us-gaap Effect Of Exchange Rate On Cash And Cash Equivalents Continuing Operations
EffectOfExchangeRateOnCashAndCashEquivalentsContinuingOperations
1000
CY2015Q1 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
3064000
CY2015Q1 us-gaap Increase Decrease In Accounts Payable
IncreaseDecreaseInAccountsPayable
111000
CY2015Q1 us-gaap Share Based Compensation
ShareBasedCompensation
803000
CY2015Q1 us-gaap Tangible Asset Impairment Charges
TangibleAssetImpairmentCharges
0
CY2015Q1 vtl Release Of Repurchase Liability For Stock Options Shares Vested During Period
ReleaseOfRepurchaseLiabilityForStockOptionsSharesVestedDuringPeriod
26000
CY2015Q1 vtl Operating Lease Agreements Expiration Year
OperatingLeaseAgreementsExpirationYear
2017
CY2015Q1 vtl Increase Decrease In Other Liabilities
IncreaseDecreaseInOtherLiabilities
-38000
CY2015Q1 vtl Fair Value Assets Between Hierarchy Levels Transfers Amount
FairValueAssetsBetweenHierarchyLevelsTransfersAmount
0

Files In Submission

Name View Source Status
0001193125-15-183945-index-headers.html Edgar Link pending
0001193125-15-183945-index.html Edgar Link pending
0001193125-15-183945.txt Edgar Link pending
0001193125-15-183945-xbrl.zip Edgar Link pending
d896318d10q.htm Edgar Link pending
d896318dex1016.htm Edgar Link pending
d896318dex311.htm Edgar Link pending
d896318dex312.htm Edgar Link pending
d896318dex321.htm Edgar Link pending
d896318dex322.htm Edgar Link pending
FilingSummary.xml Edgar Link unprocessable
Financial_Report.xls Edgar Link pending
Financial_Report.xlsx Edgar Link pending
R1.htm Edgar Link pending
R10.htm Edgar Link pending
R11.htm Edgar Link pending
R12.htm Edgar Link pending
R13.htm Edgar Link pending
R14.htm Edgar Link pending
R15.htm Edgar Link pending
R16.htm Edgar Link pending
R17.htm Edgar Link pending
R18.htm Edgar Link pending
R19.htm Edgar Link pending
R2.htm Edgar Link pending
R20.htm Edgar Link pending
R21.htm Edgar Link pending
R22.htm Edgar Link pending
R23.htm Edgar Link pending
R24.htm Edgar Link pending
R25.htm Edgar Link pending
R26.htm Edgar Link pending
R27.htm Edgar Link pending
R28.htm Edgar Link pending
R29.htm Edgar Link pending
R3.htm Edgar Link pending
R30.htm Edgar Link pending
R31.htm Edgar Link pending
R32.htm Edgar Link pending
R33.htm Edgar Link pending
R34.htm Edgar Link pending
R35.htm Edgar Link pending
R36.htm Edgar Link pending
R4.htm Edgar Link pending
R5.htm Edgar Link pending
R6.htm Edgar Link pending
R7.htm Edgar Link pending
R8.htm Edgar Link pending
R9.htm Edgar Link pending
report.css Edgar Link pending
Show.js Edgar Link pending
vtl-20150331.xml Edgar Link completed
vtl-20150331.xsd Edgar Link pending
vtl-20150331_cal.xml Edgar Link unprocessable
vtl-20150331_def.xml Edgar Link unprocessable
vtl-20150331_lab.xml Edgar Link unprocessable
vtl-20150331_pre.xml Edgar Link unprocessable